Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    19349552 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
Condition: Melanoma
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006);   Drug: Carboplatin/Paclitaxel;   Drug: Placebo

Indicates status has not been verified in more than two years